Tata India Pharma And Healthcare Fund

Type of Scheme: Primarily focuses on investment in at least 80% of its net assets in equity/equity related instruments of the companies in the Pharma & Healthcare sectors in India.

Product labelling:
- Investment in equity/equity related instruments of the companies in the Pharma & Healthcare sector in India.
- Long Term Capital Appreciation.

As on 31 October 2026

Fund Details

Date of Inception / Allotment	28 December 2015
Benchmark Name	BSE HC TRI
NAV as on October 30, 2026	
Regular Plan - Growth Option	₹ 31.8801
Regular Plan - IDCW Option	₹ 30.6604
Direct Plan - Growth Option	₹ 37.7655
Direct Plan - IDCW Option	₹ 36.5380
AUM as on October 31, 2026	₹ 1,499.08 Cr
AAUM as on October 31, 2026	₹ 1,470.49 Cr

Fund Manager Details

Name of Fund Managers	
• **Mr. Rajat Srivastava**	
Total Experience	9
Managing Since	16-Sep-2024

Minimum Investment

Lumpsum Amount	Rs. 5,000/- and in multiples of Re. 1/- thereafter.
SIP	Rs. 100/- and in multiples of Re. 1/- thereafter.

Load Structure

Exit Load: 0.25% of NAV if redeemed/switched out before 30 days from the date of allotment.

Expense Ratio

Regular plan : BER	1.81%
Direct plan : BER	0.63%

Quantitative Measures*

1	Standard Deviation (%)	16.53
2	Beta	0.98
3	Tracking Error (%)	
	1 year	NA
	3 years	NA
4	Sharpe Ratio (%)	0.72
5	Tracking Difference (%)	
	1 year	NA
	3 year	NA
	5 year	NA
	Since Inception	NA
6	Information Ratio	NA

***Please refer to the next page for detail description in tabular format**


NA stands for "Not Applicable"

Fund Performance

Compounded Annualised Returns	Scheme Returns % - Regular	Scheme Returns % - Direct	Benchmark Returns %
Returns for last 1 year	3.79	5.26	13.26
Returns for last 3 years	17.69	19.42	23.18
Returns for last 5 years	13.23	14.91	15.60
Returns since inception	11.28	13.03	11.21

Performance as on October 30, 2026.

Absolute Returns




Absolute Returns for each F.Y. for last 5 years.

Portfolio Data

	Top 10 Holdings	% to Net Assets
1	Sun Pharmaceutical Industries Ltd.	7.89%
2	Abbott India Ltd.	5.66%
3	Divi Laboratories Ltd.	5.41%
4	Healthcare Global Enterprises Ltd.	5.25%
5	Dr. Reddys Labaratories Ltd.	5.14%
6	Torrent Pharmaceuticals Ltd.	4.73%
7	Apollo Hospitals Enterprise Ltd.	4.55%
8	Max Healthcare Institute Ltd.	4.28%
9	Rainbow Childrens Medicare Ltd.	4.02%
10	Sai Life Sciences Ltd	3.22%

Scheme Riskometer


Tata India Pharma And Healthcare Fund



The risk of the scheme is Very High

Benchmark Riskometer

BSE HC TRI



The risk of the benchmark is Very High

Major Risk Factors

1	Sector bias
2	Regulatory hurdles
3	R & D reliance
4	valuation stretch

*with a detailed explanation in the Important Link Section

Quantitative Measures/Risk Measures* (as applicable)

1	Portfolio Turnover Ratio (Annualized)	
	a) Equity Turnover (%)	111.67
	b) Gross Exposure Turnover (%) (Equity + Debt + Derivatives)	111.67
2	Average Maturity (years):	NA
3	Macaulay Duration (years):	NA
4	Modified Duration (years):	NA
5	Annualized Portfolio Yield:	NA
6	Yield to Maturity (%)	NA

*** Please refer to the next page for detail description in tabular format**

NA stands for "Not Applicable"

Additional Information pertaining to Portfolio of the scheme

Detailed Investment in Securities	Click Here
Allocation of Net Asset by Sectors	Click Here
Allocation of Net Asset by Asset Class	Click Here
Allocation of Net Assets by Credit Rating	Click Here
Allocation of Net Assets by region/country	Click Here

Past Performance is not an indicator or guarantee of future results

Tata India Pharma And Healthcare Fund

TATA mutual fund

Major Changes w.r.t previous month –

As on 31 October 2026

(Top 10 changes in Holding) in portfolio of the scheme		
Name of securities added	**Name of securities deleted/reduced**	**Total Weightage in %**
Max Healthcare Institute Ltd.		4.28%
	Cipla Ltd.	4.22%
Natco Pharma Ltd.		2.86%
Aster DM Healthcare Ltd.		2.33%
Biocon Ltd.		2.23%
	Fortis Healthcare Ltd.	1.95%
Dr. Agarwals Health Care Ltd.		1.31%
Nestle India Ltd.		1.09%
	Mankind Pharma Ltd.	0.77%
	Jubilant Pharmova Ltd.	0.00%

Changes in Expense Ratio of the scheme		
Change in	**Previous Month**	**Current Month**
Direct	0.63%	0.63%
Regular	1.80%	1.81%

Changes in Credit Quality		
Name of security	**Rating Previous Month**	**Rating Current Month**
NA	NA	NA

Changes in Risk-o-Meter of scheme		
Fund Name	**Previous Month**	**Current Month**
Scheme Riskometer	Very High	Very High

Description/inference of the Quantitative/Risk Measures

Sr. No.	Quantitative Measures/Risk Measures	Brief description/ Inference of the Quantitative measure
1	Standard Deviation	Measures the volatility of the fund
2	Beta	Shows fund's sensitivity to market movements
3	Sharpe Ratio	Evaluates the excess return generated per unit of risk
4	Tracking Error	Indicates how closely fund tracks the Benchmark
5	Tracking Difference	Difference between the fund and its benchmark return
6	Portfolio Turnover Ratio	Indicates how actively the portfolio changes
7	Average Maturity	Weighted average residual maturity
8	Macaulay Duration	Fund's sensitivity to interest rate changes
9	Modified Duration	Fund's sensitivity to interest rate changes
10	Annualized Portfolio Yield	Total income generated by the portfolio
11	Yield to Maturity	weighted average expected annual return

Important Weblinks

Sr. No.	Links	Description
1	Video Explainer	Link for a video providing simplified explanation of the Fund Factsheet along with explanation to various terminologies used.
2	Calculation/Methodology	Link for a pdf showing the various mathematical parameters and their respective Calculation methodology/formulae along with any assumptions considered.
3	Detailed Risk Factors	Link to be provided for various risk factors associated with the Scheme.
4		Link for SID on AMC website.
5	Investor Services	Link showing Contact details (Email ID and Telephone Number of the Investor.
6	Grievance submission and redressal	Link directing to grievance submission page with details showing Escalation matrix.

Tata India Pharma And Healthcare Fund

TATA mutual fund

Additional Disclosure by AMC

As on 31 October 2026

Investment Objective

The investment objective of the scheme is to seek long term capital appreciation by investing atleast 80% of its net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.However, there is no assurance or guarantee that the investment objective of the Scheme will be achieved.The Scheme does not assure or guarantee any returns.

SIP - If you had invested INR 10,000 every month

	1 Year	3 Year	5 Year	7 Year	10 Year	Since Inception
Total Amount Invested (Rs.)	1,20,000	3,60,000	6,00,000	8,40,000	12,00,000	13,10,000
Total Value as on Oct 31, 2026 (Rs.)	1,23,734	4,05,162	8,54,663	14,65,281	27,69,050	31,31,189
Returns	5.86%	7.85%	14.14%	15.63%	15.96%	15.13%
Total Value of B: BSE HC TRI	1,31,778	4,47,346	9,61,015	16,52,258	30,00,601	33,69,264
B: BSE HC TRI	18.82%	14.66%	18.93%	19.00%	17.46%	16.36%
Total Value of AB: Nifty 50 TRI	1,14,112	3,57,100	6,83,449	11,61,750	20,57,692	24,15,973
AB: Nifty 50 TRI	-9.02%	-0.53%	5.16%	9.12%	10.40%	10.74%

(Inception date :28-Dec-2015) (First Installment date : 01-Jan-2016)

Past performance may or may not be sustained in the future. Returns greater than 1 year period are compounded annualized. Income Distribution cum capital withdrawals are assumed to be reinvested and bonus is adjusted. Load is not taken into consideration. For SIP returns, monthly investment of equal amounts invested on the 1st day of every month has been considered. For scheme performance refer pages 220 - 251.

*B: Benchmark, AB: Additional Benchmark. For Scheme Risk-O-Meter and Scheme Benchmark Risk-O-Meter please refer page number 252 of Factsheet.

Source: MFI Explorer

Market Capitalisation wise Exposure

Large Cap	26.82%
Mid Cap	31.07%
Small Cap	42.11%

Market Capitalisation is as per list provided by AMFI.

NAV Movement

